GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » E10

CYTH (Cyclo Therapeutics) E10 : $-4.97 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cyclo Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.310. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-4.97 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was -8.30% per year. During the past 5 years, the average E10 Growth Rate was -7.80% per year. During the past 10 years, the average E10 Growth Rate was -21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cyclo Therapeutics was 9.00% per year. The lowest was -93.40% per year. And the median was -8.30% per year.

As of today (2024-12-13), Cyclo Therapeutics's current stock price is $0.60. Cyclo Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-4.97. Cyclo Therapeutics's Shiller PE Ratio of today is .


Cyclo Therapeutics E10 Historical Data

The historical data trend for Cyclo Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics E10 Chart

Cyclo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.62 -3.80 -3.97 -4.44 -4.83

Cyclo Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.86 -4.83 -4.97 -4.98 -4.97

Competitive Comparison of Cyclo Therapeutics's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Shiller PE Ratio falls into.



Cyclo Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cyclo Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.31/133.0289*133.0289
=-0.310

Current CPI (Sep. 2024) = 133.0289.

Cyclo Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.583 99.070 -0.783
201503 -1.000 99.621 -1.335
201506 -1.000 100.684 -1.321
201509 -1.000 100.392 -1.325
201512 -2.000 99.792 -2.666
201603 -1.000 100.470 -1.324
201606 -2.000 101.688 -2.616
201609 -2.000 101.861 -2.612
201612 -2.000 101.863 -2.612
201703 -1.000 102.862 -1.293
201706 -1.000 103.349 -1.287
201709 -1.000 104.136 -1.277
201712 -2.000 104.011 -2.558
201803 -1.000 105.290 -1.263
201806 -2.000 106.317 -2.503
201809 -1.000 106.507 -1.249
201812 -1.000 105.998 -1.255
201903 -2.000 107.251 -2.481
201906 -1.000 108.070 -1.231
201909 -1.000 108.329 -1.228
201912 -2.168 108.420 -2.660
202003 -2.167 108.902 -2.647
202006 -1.548 108.767 -1.893
202009 -0.845 109.815 -1.024
202012 -0.562 109.897 -0.680
202103 -0.760 111.754 -0.905
202106 -0.560 114.631 -0.650
202109 -0.600 115.734 -0.690
202112 -0.340 117.630 -0.385
202203 -0.330 121.301 -0.362
202206 -0.410 125.017 -0.436
202209 -0.500 125.227 -0.531
202212 -0.590 125.222 -0.627
202303 -0.460 127.348 -0.481
202306 -0.330 128.729 -0.341
202309 -0.290 129.860 -0.297
202312 -0.230 129.419 -0.236
202403 -0.150 131.776 -0.151
202406 -0.210 132.554 -0.211
202409 -0.310 133.029 -0.310

Add all the adjusted EPS together and divide 10 will get our e10.


Cyclo Therapeutics  (NAS:CYTH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cyclo Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850

Cyclo Therapeutics Headlines

From GuruFocus